S. Taylor

Whole genome and transcriptome analysis enhances precision cancer treatment options.

K. Savage, E. Pleasance, M. Marra, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers.

K. Gelmon, S. Peacock, C. Lohrisch, 2012 .

Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma.

Steven J. M. Jones, E. Pleasance, M. Marra, 2019, JCO precision oncology.

Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

P. Goodwin, K. Pritchard, M. Trudeau, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

E. Eisenhauer, K. Gelmon, M. Tsao, 2017, Breast Cancer Research.

Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry

L. Eriksson, J. Bergh, J. Hartman, 2018, Breast Cancer Research and Treatment.

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

A. Oza, S. Chia, M. Clemons, 2010, The oncologist.

Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls

P. Goodwin, M. Ennis, A. E. Lohmann, 2017, Breast Cancer Research and Treatment.

The Sorting Out Stress Cards—A Version of the SMQ

F. Stein, S. Taylor, Daphne Grueschow, 2003 .

Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors

A. Tolcher, Lixin Lang, S. Alberts, 2009 .

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

E. Eisenhauer, K. Gelmon, M. Tsao, 2017, Breast Cancer Research.